Racial Differences in Markers of Mineral Metabolism in Advanced Chronic Kidney Disease


Summary

Background and objectives This study examined differences in the concentration of markers of mineral metabolism across race in patients with advanced CKD not requiring dialysis and ESRD.

Design, setting, participants, & measurements Concentrations of 25-hydroxyvitamin D (25(OH)D), 1,25-dihydroxyvitamin D (1,25(OH)2D), intact parathyroid hormone (iPTH), and fibroblast growth factor 23 (FGF-23) were measured in stored plasma samples of 1497 patients with advanced CKD not yet on dialysis and ESRD who participated in the Homocysteine in Kidney and End Stage Renal Disease study. Linear regression models were used to examine the relationship between race and 25(OH)D, 1,25(OH)2D, iPTH, and FGF-23 concentrations.

Results Non-Hispanic white patients comprised 58% of the cohort, whereas non-Hispanic blacks comprised 42%. Median (interquartile range) FGF-23 concentrations were lower in blacks compared with whites with CKD (323 [181–655] versus 431 [232–1026] RU/ml; P<0.001) but not in ESRD. In adjusted linear regression models, blacks with CKD not requiring dialysis had significantly lower plasma FGF-23 concentrations (difference, −159; 95% confidence interval, −205 to −106; P<0.001) compared with whites, independent of plasma 25(OH)D, 1,25(OH)2D, and iPTH concentrations. This difference was not observed in the ESRD group. The magnitude of correlation for the relationships between 1,25(OH)2D with iPTH, FGF-23 with 1,25(OH)2D, and FGF-23 with iPTH were stronger among blacks than whites with CKD not requiring dialysis.

Conclusions In advanced CKD not requiring dialysis, blacks have lower FGF-23 concentrations than whites. Blacks with CKD and ESRD have lower 25(OH)D and higher iPTH compared with whites, independent of FGF-23 concentrations.

Introduction

Abnormalities in 25-hydroxyvitamin D (25(OH)D), 1,25-dihydroxyvitamin D (1,25(OH)2D), intact parathyroid hormone (iPTH), and phosphate homeostasis have been linked to all-cause mortality and cardiovascular disease (CVD) including vascular calcification, left ventricular hypertrophy, and hypertension in patients with kidney disease (1–10). The recent discovery of fibroblast growth factor 23 (FGF-23) and its phosphaturic effect (11,12) has added another important variable to disordered mineral metabolism in CKD. High FGF-23 concentrations have been independently linked to death and CVD, including increased arterial medial calcification and left ventricular hypertrophy, in animal models, in the general population, and in patients with mild to moderate CKD (7,8,13).

Adding to the complexity of the abnormal mineral metabolism axis in CKD not requiring dialysis and ESRD is the observation that dissimilarities exist among different races (14,15). Black patients tend to have lower 25(OH)D levels and higher iPTH levels compared with whites (16–18). FGF-23 concentrations also seem to vary across race and kidney disease stage. A recent nested case-control analysis showed that blacks with ESRD had lower concentrations of FGF-23 compared with whites (19). These differences have not been thoroughly examined in CKD patients not requiring dialysis. Hence, understanding differences in mineral metabolism across race and kidney function strata is of pivotal importance because this may have important implications for screening and treatment.

We evaluated the distribution of plasma 25(OH)D, 1,25(OH)2D, iPTH, and FGF-23 concentrations in 1497 non-Hispanic blacks and non-Hispanic whites with either severe CKD, not yet on dialysis, or ESRD who participated in the Homocysteine in Kidney and End Stage Renal Disease (HOST) study (20).

Materials and Methods

Study Participants

The details of the HOST study have been described previously (20). Briefly, the study was a multicenter, prospective, randomized, double-blind, placebo-controlled trial examining the effects of high doses of folic acid, pyridoxine hydrochloride (vitamin B6),...
and cyanocobalamin (vitamin B<sub>12</sub>) on death and cardiovascular events in patients with advanced kidney disease and elevated homocysteine concentrations. The trial enrolled 2056 participants from 36 Veterans Affairs medical centers between September 2001 and October 2003. Patients were included in the study if they were aged ≥21 years with ESRD receiving either hemodialysis or peritoneal dialysis (n=751), or with an estimated creatinine clearance (calculated by the Cockcroft-Gault formula) of <30 ml/min but not yet on chronic dialysis (n=1305) and an elevated plasma homocysteine concentration of ≥15 μmol/L.

**Measurements**

We used stored EDTA blood samples collected from the participants 3 months after randomization for measurement of plasma 25(OH)D, 1,25(OH)<sub>2</sub>D, iPTH, and FGF-23 concentrations. We measured 25(OH)D concentrations by a commercial competitive chemiluminescent immunoassay on a Liaison analyzer and 1,25(OH)<sub>2</sub>D concentrations by a commercial competitive RIA (both from DiaSorin, Stillwater, MN). 25(OH)D measurements were not calibrated to the National Institute of Standards and Technology because reference material (SRM 972) did not become available until after the study measurements were complete.

The analytical measurement range for the 25(OH)D assay is 7–150 ng/ml. The intra-assay coefficients of variation (CVs) were 5.6% and 4.5% at 11 and 28 ng/ml, respectively. The interassay CVs were 9.1% and 5.6% at 16 and 51 ng/ml, respectively. For 1,25(OH)<sub>2</sub>D, the range of the assay was 5–200 pg/ml. The intra-assay CVs were 12.6% and 9.7% at 13 and 45 pg/ml, respectively. The interassay CVs were 21.4% and 14.7% at 25 pg/ml and 56 pg/ml, respectively. C-terminal FGF-23 concentrations were measured using a two-site second-generation ELISA kit (Immutopics, San Clemente, CA) with antibodies directed against two epitopes within the C-terminal region of the FGF-23 molecule (21). The analytical measurement range for the FGF-23 assay was 3.0–2300 RU/ml. The CVs were 2.6% and 1.4% at 32.1 and 299.2 RU/ml, respectively. The interassay CVs were 3.4% and 4.4% at 32.1 and 299.2 RU/ml, respectively. iPTH was measured using a Roche E170 electrochemiluminescent immunoassay with a reference interval of 15–65 pg/ml. The intra- and interassay CVs were both <5%.

**Other Measurements**

Information collected at the time of randomization included a complete history and physical examination; history of hypertension, diabetes, and CVD identified by self-report and chart review; and use of medications including angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), β blockers, and lipid-lowering drugs. Serum creatinine was measured at local sites and was assessed by spectrophotometry analysis using the modified kinetic Jaffe reaction (22) at all sites. To note, although a creatinine clearance estimated by the Cockcroft-Gault formula was used for eligibility of the HOST study, for the purpose of this analysis, estimated GFR (eGFR) was estimated using the four-variable Modified Diet Renal Disease (MDRD) prediction equation (23).

**Statistical Analyses**

Patients were excluded if EDTA-plasma samples were not available for vitamin D and FGF-23 measurements (n=335) and/or if race was nonwhite or nonblack, categorized as other (n=224), resulting in a final sample of 1497 participants in this study (Figure 1). Two-sample t tests or Wilcoxon rank-sum tests for continuous variables and Pearson chi-squared tests for categorical variables were used to compare baseline characteristics among whites and blacks in the whole cohort. We tested for racial differences in concentrations of calcium, phosphorus, 25(OH)D, 1,25(OH)<sub>2</sub>D, iPTH, and FGF-23 on a continuous scale in groups according to CKD stage (advanced CKD or ESRD). In addition, we examined the overall and stage-specific racial differences in the prevalence of 25(OH) deficiency (<15 ng/ml), elevated iPTH (>65 pg/ml), and FGF-23 (above kidney disease stage-specific median concentration). These thresholds were chosen in keeping with the definition for 25(OH)D deficiency and elevated iPTH and FGF-23 concentrations published in previous reports (24–26). Spearman correlations and graphical methods were used to investigate the correlation of 25(OH)D, 1,25(OH)<sub>2</sub>D, iPTH, and FGF-23 concentrations with one another and with eGFR across race and kidney function strata.

Multivariable linear regression models were used to examine the associations among races and plasma concentrations of 25(OH)D, 1,25(OH)<sub>2</sub>D, iPTH, and FGF-23. Given the skewed distribution of these markers of mineral metabolism, the values were transformed to the log base of 10 for all analyses. As the dependent variable (i.e., 25(OH)D, 1,25(OH)<sub>2</sub>D, iPTH, and FGF-23) of the regression was logged, model-predicted values for each dependent variable were anti-logged and the differences between blacks and whites and respective 95% confidence intervals (95% CIs) were reported for each dependent variable.

The covariates for adjustment in the final models were primarily identified if they were significantly correlated with abnormalities of mineral metabolism and were deemed to be biologically plausible. Two sequential sets of covariates were considered. In model 1, the covariates included age, sex, season, CVD, hypertension, diabetes, body mass index, serum calcium, and phosphate. Vintage and eGFR were included as potential confounders in regression models for ESRD and CKD, respectively. In model 2, the covariates included those used in model 1 plus the other three markers of mineral metabolism. All statistical analyses were performed with SAS software (version 9.13; SAS Institute, Cary, NC).

**Results**

**Baseline Characteristics**

There were a total of 1497 participants analyzed, of whom 58% (873) were white and 42% (624) were black. Baseline characteristics from the cohort are presented in Table 1. Whites were older and smoked less than blacks. Although all participants had a similar prevalence of hypertension, blacks had higher systolic and diastolic BPs. Diabetes was more prevalent among blacks, whereas a history of CVD was more prevalent among whites. To note, whites were more likely to be treated with cardioprotective medications than blacks.
Mineral Metabolism in CKD and ESRD by Race

In whites with advanced CKD not requiring dialysis, 25(OH)D correlated with 1,25(OH)₂D (r=0.42, P<0.001) and iPTH (r=−0.23, P<0.001). Similarly, in blacks with CKD not requiring dialysis, 25(OH)D correlated with 1,25(OH)₂D (r=0.47, P<0.001) and iPTH (r=−0.23, P<0.001). Furthermore, 1,25(OH)₂D correlated with iPTH in whites (r=−0.10, P=0.02) and in blacks (r=−0.31, P<0.001), as well as with FGF-23 in whites (r=−0.42, P<0.001) and in blacks (r=−0.44, P<0.001). Finally, iPTH correlated with FGF-23 in whites (r=0.30, P<0.001) and in blacks (r=0.48, P<0.001). Interestingly, there were significant interactions for the relationships of 1,25(OH)₂D with iPTH, FGF-23 with 1,25(OH)₂D, and FGF-23 with iPTH by race (Figure 2, A–C).
Figure 2. Bivariate relationship of markers of mineral metabolisms in patients with CKD not requiring dialysis with interaction by race. (A) Relation between 1,25(OH)$_2$D and iPTH, (B) FGF-23 and 1,25(OH)$_2$D, and (C) FGF-23 and iPTH.
There were fewer correlations in ESRD. Our results showed that 25(OH)D correlated with 1,25(OH)₂D in whites ($r=0.40, P<0.001$) and in blacks ($r=0.33, P<0.001$). Intact parathyroid hormone (iPTH) correlated with FGF-23 in whites ($r=0.29, P<0.001$) and in blacks ($r=0.23, P<0.001$). The stronger correlation between iPTH and FGF-23 in blacks with CKD was not observed in the ESRD group and there were no significant interactions by race for any of these bivariate relationships (not shown) (Supplemental Materials).

In the group with CKD not requiring dialysis, the relationship between each mineral metabolism variable with eGFR was also examined and was statistically significant for 1,25(OH)₂D, iPTH, and FGF-23 in both whites and blacks (i.e., plasma 1,25(OH)₂D decreased and iPTH and FGF-23 increased with declining eGFR similarly in whites and blacks; $P<0.05$ for all). For both blacks and whites, the relationship between eGFR and 25(OH)D was not significant ($P>0.10$ for both). We found a significant interaction between eGFR and race for iPTH ($P<0.001$). In further evaluation of this interaction, we noted that iPTH increased by 8.30 pg/ml and by 3.23 pg/ml for each 1 ml/min per 1.73 m$^2$ decrease in eGFR for blacks and whites, respectively. No differences were observed between mineral metabolism variables and dialysis vintage in the ESRD group.

Table 2 shows the concentration of the mineral metabolism markers across race in HOST participants with CKD not requiring dialysis and ESRD, respectively. Among participants with CKD not on chronic dialysis (Table 2), blacks had lower concentrations of 25(OH)D than whites (14 ng/ml [9–19] versus 21 ng/ml [15–28], $P<0.001$) and higher concentrations of iPTH (187 pg/ml [108–328] versus 129 [77–216], $P<0.001$). There were no statistically significant differences in serum phosphate concentrations and kidney function across races in participants with CKD not requiring dialysis. FGF-23 concentrations were lower in blacks than nonblacks (323 RU/ml [181–655] versus 431 RU/ml [232–1026], $P<0.001$). In participants with ESRD (Table 2), blacks also had lower 25(OH)D concentrations (13 ng/ml [9–19] versus 17 ng/ml [12–24], $P<0.001$) and higher iPTH (225 pg/ml [135–430] versus 136 pg/ml [87–317], $P<0.001$) concentrations than nonblacks. No statistically significant differences were observed in FGF-23 concentration (3914 RU/ml [1350–13,682] versus 4036 [95% CI, 1393–12,878], $P=0.73$). As in CKD, there was no difference in serum phosphorus concentrations across races in patients with ESRD. To note, blacks had been receiving chronic dialysis longer (vintage) than whites. No difference in the concentrations of mineral metabolism markers were observed on the basis of randomization to either the intervention group or the placebo group in the original study across kidney function strata.

In general, 25(OH)D concentrations were lower in ESRD compared with CKD not requiring chronic dialysis (15 [10–21] versus 19 [12–26] ng/ml, $P<0.001$). A higher percentage of blacks had a 25(OH)D concentration <15 ng/ml (59.9% of blacks with CKD versus 28.0% of whites with CKD and 63.4% of blacks with ESRD versus 41.5% of whites with ESRD; $P<0.001$ for both). 25(OH)D concentrations <30 ng/ml were highly prevalent among all groups.
Secondary hyperparathyroidism defined as an iPTH >65 pg/mL had approximately equal prevalence in advanced CKD and ESRD and blacks had a higher prevalence in both groups than whites (91.4% of blacks with CKD versus 82.2% of whites with CKD and 89.8% of blacks with ESRD versus 83.3% of whites with ESRD; P < 0.001 for both). Similar results were observed when secondary hyperparathyroidism was defined as an iPTH >110 pg/mL or an iPTH >300 pg/mL for CKD not yet on dialysis and ESRD, respectively. Among participants with CKD not requiring dialysis, FGF-23 concentrations greater than the median value (273 RU/mL) were more prevalent in whites than blacks (52.7% versus 43.8%; P = 0.001) and whites versus blacks (52.7% versus 43.8%; P = 0.001). Similarly, for participants with ESRD, FGF-23 concentrations greater than the median value (563 RU/mL) were more prevalent in whites than blacks (55.1% versus 36.6%; P < 0.001). Similarly, for participants with ESRD, FGF-23 concentrations greater than the median value (563 RU/mL) were more prevalent in whites than blacks (55.1% versus 36.6%; P < 0.001). Similarly, for participants with ESRD, FGF-23 concentrations greater than the median value (563 RU/mL) were more prevalent in whites than blacks (55.1% versus 36.6%; P < 0.001). Similarly, for participants with ESRD, FGF-23 concentrations greater than the median value (563 RU/mL) were more prevalent in whites than blacks (55.1% versus 36.6%; P < 0.001).

In participants with CKD not requiring dialysis, black race was associated with significantly lower 25(OH)D concentrations than whites in both the unadjusted and fully adjusted models with a difference of −4.11 (95% CI, −2.80 to −5.29; P < 0.001) in the fully adjusted model. The iPTH concentration was higher in blacks in both the unadjusted and adjusted models with a difference of 63.55 (95% CI, 29.89–103.57; P < 0.001) in the fully adjusted model. Blacks with ESRD also had higher 1,25(OH)2D concentrations compared with whites only after adjustment for 25(OH)D, with a difference of 1.90 (95% CI, 0.69–3.24; P = 0.002). There was no difference between races when plasma FGF-23 concentrations were modeled for the ESRD group. Finally, results remained unchanged when linear regression analyses for the CKD and ESRD group were restricted only to male patients.

### Discussion

In this cross-sectional study of 1497 patients with kidney disease, we found that blacks have significantly lower 25(OH)D concentrations and higher iPTH concentrations than whites. FGF-23 was significantly lower in blacks than in whites in patients with CKD, whereas there was no association between race and FGF-23 concentrations in multivariate linear regression models in patients with ESRD. To our knowledge, this is the first study to evaluate racial differences in FGF-23 concentrations in predialysis CKD and ESRD patients, independent of 25(OH)D, 1,25(OH)2D, and iPTH concentrations.

FGF-23 has received attention recently for its potential role in the increased risk of CVD and death in patients with CKD. Racial differences in FGF-23 concentrations have been reported in the dialysis population, but not in predialysis CKD patients. Gutiérrez et al. found that the median FGF-23 concentrations were significantly lower in blacks initiating dialysis than in whites and Hispanics (19). We found no significant racial differences in FGF-23 concentrations in dialysis patients; however, in contrast to the study by Gutiérrez et al., our dialysis cohort was not new to dialysis and most had been receiving renal replacement therapy for ≥2 years. In patients with severe

### Table 2. Distribution of markers of mineral metabolism across race in patients with CKD not requiring chronic dialysis and ESRD

<table>
<thead>
<tr>
<th>Marker</th>
<th>Non-Hispanic White</th>
<th>Non-Hispanic Black</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CKD not requiring chronic dialysis</td>
<td>(n=622)</td>
<td>(n=290)</td>
<td>0.02</td>
</tr>
<tr>
<td>serum calcium (mg/dl)</td>
<td>8.9±0.7</td>
<td>9.0±0.7</td>
<td>0.09</td>
</tr>
<tr>
<td>serum phosphate (mg/dl)</td>
<td>4.3±1.2</td>
<td>4.4±1.7</td>
<td>0.09</td>
</tr>
<tr>
<td>25-hydroxyvitamin D (ng/ml)</td>
<td>21 (15–28)</td>
<td>14 (9–19)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>1,25-dihydroxyvitamin D (pg/ml)</td>
<td>17 (12–26)</td>
<td>18 (12–25)</td>
<td>0.67</td>
</tr>
<tr>
<td>intact parathyroid hormone (pg/ml)</td>
<td>129 (77–216)</td>
<td>187 (108–328)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>fibroblast growth factor-23 (RU/ml)</td>
<td>431 (232–1026)</td>
<td>323 (181–655)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>estimated GFR (ml/min per 1.73 m²)</td>
<td>18±6</td>
<td>19±7</td>
<td>0.06</td>
</tr>
<tr>
<td>ESRD</td>
<td>(n=251)</td>
<td>(n=334)</td>
<td></td>
</tr>
<tr>
<td>serum calcium (mg/dl)</td>
<td>9.3±1.0</td>
<td>9.1±0.9</td>
<td>0.001</td>
</tr>
<tr>
<td>serum phosphate (mg/dl)</td>
<td>5.6±1.8</td>
<td>5.5±1.8</td>
<td>0.53</td>
</tr>
<tr>
<td>25-hydroxyvitamin D (ng/ml)</td>
<td>17 (12–24)</td>
<td>13 (9–19)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>1,25-dihydroxyvitamin D (pg/ml)</td>
<td>12 (8–16)</td>
<td>12 (8–18)</td>
<td>0.73</td>
</tr>
<tr>
<td>intact parathyroid hormone (pg/ml)</td>
<td>136 (87–317)</td>
<td>225 (135–430)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>fibroblast growth factor-23 (RU/ml)</td>
<td>4036 (1393–12,878)</td>
<td>3914 (1350–13,682)</td>
<td>0.73</td>
</tr>
<tr>
<td>time on dialysis (d)</td>
<td>712±1018</td>
<td>950±1343</td>
<td>0.02</td>
</tr>
</tbody>
</table>

Data expressed as mean ± SD or median (interquartile range).
Black versus white. Model 1 adjusted for age, sex, season, cardiovascular disease, hypertension, diabetes, body mass index, estimated GFR, serum calcium, and serum phosphorus. 25(OH)D, 25-hydroxyvitamin D; 1,25(OH)2D, 1,25-dihydroxyvitamin D; iPTH, intact parathyroid hormone; FGF-23, fibroblast growth factor 23; 95% CI, 95% confidence interval.

aModel 2 adjusted for model 1 + 1,25(OH)2D, iPTH, and FGF-23.

bModel 2 adjusted for model 1 + 25(OH)D, iPTH, and FGF-23.

cModel 2 adjusted for model 1 + 25(OH)D, 1,25(OH)2D, and FGF-23.

dModel 2 adjusted for model 1 + 25(OH)D, 1,25(OH)2D, and iPTH.

Table 3. Relationship between race and markers of mineral metabolism in patients with CKD not requiring chronic dialysis and ESRD

<table>
<thead>
<tr>
<th>Model</th>
<th>25(OH)D</th>
<th>1,25(OH)2D</th>
<th>iPTH</th>
<th>FGF-23</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Difference (95% CI)</td>
<td>P Value</td>
<td>Difference (95% CI)</td>
<td>P Value</td>
</tr>
<tr>
<td>CKD not requiring chronic dialysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>unadjusted</td>
<td>-5.88 (-6.82 to -4.88)</td>
<td>&lt;0.001</td>
<td>0.04 (-1.17 to 1.33)</td>
<td>0.95</td>
</tr>
<tr>
<td>model 1</td>
<td>-5.52 (-6.49 to -4.48)</td>
<td>&lt;0.001</td>
<td>0.16 (-0.99 to 1.40)</td>
<td>0.79</td>
</tr>
<tr>
<td>model 2</td>
<td>-4.33 (-5.67 to -3.48)</td>
<td>&lt;0.001</td>
<td>1.50 (0.35–2.72)</td>
<td>0.01</td>
</tr>
<tr>
<td>ESRD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>unadjusted</td>
<td>-4.09 (-5.26 to -2.81)</td>
<td>&lt;0.001</td>
<td>0.46 (-0.60 to 1.61)</td>
<td>0.41</td>
</tr>
<tr>
<td>model 1</td>
<td>-3.93 (-5.19 to -2.54)</td>
<td>&lt;0.001</td>
<td>0.80 (-0.35 to 2.06)</td>
<td>0.18</td>
</tr>
<tr>
<td>model 2</td>
<td>-4.11 (-2.80 to -5.29)</td>
<td>&lt;0.001</td>
<td>1.90 (0.69–3.24)</td>
<td>0.002</td>
</tr>
</tbody>
</table>
screening and treatment guidelines are adequate for all races/ethnicities.

Acknowledgments

We thank William E. Owen for assistance with the plasma FGF-23 assay.

The research reported in this study was supported by the Department of Veterans Affairs Cooperative Studies Program and the HOST Executive Committee members Rex L. Jamison, Pamela Hartigan, James Kaufman, David S. Goldfarb, Stuart R. Warren, Peter D. Guarino, and Michael Gazzano. Additional support came from the National Institute of Diabetes and Digestive and Kidney Disease Grants K23DK087859-01A1, R01 DK081473, and R01 DK078112, as well as an Amgen fellowship grant and an investigator initiated proposal funded by Genzyme and Abbott.

Disclosures

None.

References


Received: July 12, 2011 Accepted: January 18, 2012

Published online ahead of print. Publication date available at www.cjasn.org.

This article contains supplemental material online at http://cjasn.asnjournals.org/lookup/suppl/doi:10.2215/CJN.07020711/-/DCSupplemental.